Evidence map›Paper›PMID 39315395›Full record

ReviewMaterials today. Bio2024

Metallic nano-warriors: Innovations in nanoparticle-based ocular antimicrobials.

Mingyou Zhang, Yuhang Cheng, Hongjin Li, Mengdie Li, Qixiang Yang, Kaifang Hua, Xiaofei Wen, Yun Han, Gang Liu, Chengchao Chu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingyou ZhangXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Yuhang ChengXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Hongjin LiXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Mengdie LiXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Qixiang YangFujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Xiamen, Fujian, China.
Kaifang HuaFujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Xiamen, Fujian, China.
Xiaofei WenDepartment of Interventional Radiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen, Fujian, 361000, China.
Yun HanXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Gang LiuState Key Laboratory of Physical Chemistry of Solid Surfaces & the MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361002, China.
Chengchao ChuXiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eye infection is one of the most important causes of blindness. Due to the particularity of ocular structure, the enhancement of bacteria resistance, and the significant side effects of long-term medication, it is difficult to treat ocular antimicrobial diseases. The efficacy of medications currently employed is progressively becoming more restricted. The research and development of novel antimicrobial drugs is imperative and imminent in order to overcome the bottleneck problem. Metal nanoparticles have been developed rapidly in the field of biomedicine because of their brilliant antibacterial activity, long-lasting effect, and great bioavailability. Efficacy and biosafety proven in in vitro and in vivo experiments demonstrate the promising prospect of metal nanoparticles for ocular antimicrobial therapy. Based on the development status of antibacterial metal nanoparticles in ophthalmology, we summarized the antibacterial mechanism of metal nanoparticles and the application of nano-antibacterial drugs in this field, emphasizing their advantages over conventional drugs, thus guiding clinical ophthalmic antibacterial therapy.

Indexed as

Drug delivery systemMetal nanoparticlesOcular antibacterial

Identifiers

PMID39315395
PMCPMC11419815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.